Price movement over the last 24 hours
Abeona Therapeutics Inc vs General Motors Company — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while General Motors Company trades at $76.01 (market cap $68.55B). The key difference: General Motors Company is far larger — about 183.6× Abeona Therapeutics Inc's market cap, and General Motors Company pays a 0.95% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | GM | |
|---|---|---|
Market Cap | $373.32M | $68.55B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $86.38 |
52-Week Low | $4.17 | $48.89 |
Enterprise Value | $228.22M | $171.89B |
Dividend Yield | — | 0.95% |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →